GlaxoSmithKline Pharmaceuticals Ltd Stock Price Today (NSE: GLAXO)
Fundamental Score
GlaxoSmithKline Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
GlaxoSmithKline Pharmaceuticals Ltd share price today is ₹2436.70, down 0.70% on NSE/BSE as of 20 April 2026. GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹42.32K (Cr). The 52-week high for GLAXO share price is ₹3515.70 and the 52-week low is ₹2217.60. At a P/E ratio of 44.39x, GLAXO is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 46.87% and a debt-to-equity ratio of 0.02.
GlaxoSmithKline Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Institutional Deep-Dive
Bull Run Research Hub
GlaxoSmithKline Pharmaceuticals Share Price: A ROCE-Focused Analysis
The pharmaceutical industry, characterized by lengthy R&D cycles and stringent regulatory approvals, often sees delayed translation of innovation into immediate profitability. This backdrop informs our analysis of the GlaxoSmithKline Pharmaceuticals share price. Currently trading at ₹2484.0 with a PE ratio of 44.39, GlaxoSmithKline Pharmaceuticals Ltd exhibits a remarkable Return on Capital Employed (ROCE) of 63.25%. This analysis is based on publicly available data and is part of an 80-parameter fundamental audit verified by Sweta Mishra.
The exceptionally high ROCE figure of 63.25% warrants further scrutiny. It suggests that GlaxoSmithKline Pharmaceuticals Ltd is generating significant profits from its invested capital. A high ROCE can be a strong indicator of a company's competitive advantage, often referred to as its economic "moat." In GlaxoSmithKline Pharmaceuticals Ltd's case, this moat could stem from patented drugs, strong brand recognition, or efficient operational management. The ability to consistently generate high returns on capital allows the company to reinvest earnings for future growth, potentially funding further R&D or strategic acquisitions. However, it is important to assess the sustainability of this high ROCE in the face of potential patent expirations and increasing generic competition.
When compared to sector peers, such as
Mankind Pharma Ltd, a deeper analysis of management quality is crucial. While quantitative metrics provide an initial assessment, qualitative factors such as strategic decision-making, risk management, and capital allocation play a vital role in long-term performance. Comparing GlaxoSmithKline Pharmaceuticals Ltd's management effectiveness with that of Mankind Pharma Ltd would require examining factors such as their respective track records in bringing new drugs to market, their ability to navigate regulatory hurdles, and their overall capital allocation strategies. A superior management team, even with a similar ROCE, might suggest a more sustainable competitive advantage.In conclusion, while the high ROCE of GlaxoSmithKline Pharmaceuticals Ltd is an encouraging sign, a comprehensive evaluation should consider the sustainability of this performance, the company's competitive landscape, and the effectiveness of its management team relative to peers. This analysis is purely observational and does not constitute financial advice.
GlaxoSmithKline Pharmaceuticals Ltd Share Price — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2293.10 | ₹2339.80 | ₹2261.90 | ₹2311.50 | 1.09L (Cr) | |
| ₹2305.00 | ₹2401.90 | ₹2291.20 | ₹2329.20 | 70.12K (Cr) | |
| ₹2259.50 | ₹2296.90 | ₹2217.60 | ₹2283.00 | 1.30L (Cr) | |
| ₹2320.60 | ₹2330.40 | ₹2255.10 | ₹2259.50 | 61.07K (Cr) | |
| ₹2310.00 | ₹2352.50 | ₹2310.00 | ₹2339.80 | 57.83K (Cr) | |
| ₹2301.00 | ₹2340.00 | ₹2284.60 | ₹2309.10 | 51.35K (Cr) | |
| ₹2353.40 | ₹2364.90 | ₹2269.10 | ₹2279.20 | 50.96K (Cr) | |
| ₹2376.80 | ₹2416.00 | ₹2362.50 | ₹2384.80 | 58.87K (Cr) | |
| ₹2401.00 | ₹2419.60 | ₹2372.40 | ₹2376.70 | 23.01K (Cr) | |
| ₹2428.90 | ₹2472.00 | ₹2418.20 | ₹2437.60 | 26.38K (Cr) |
GlaxoSmithKline Pharmaceuticals Ltd Share Price History — Last 12 Months
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2305.00 | ₹2401.90 | ₹2261.90 | ₹2311.50 | +0.28% | |
| ₹2520.00 | ₹2581.60 | ₹2217.60 | ₹2283.00 | -9.40% | |
| ₹2400.20 | ₹2719.80 | ₹2342.10 | ₹2571.60 | +7.14% | |
| ₹2476.00 | ₹2528.00 | ₹2220.30 | ₹2401.60 | -3.00% | |
| ₹2551.00 | ₹2635.00 | ₹2362.60 | ₹2473.60 | -3.03% | |
| ₹2644.00 | ₹2694.00 | ₹2404.20 | ₹2569.50 | -2.82% | |
| ₹2659.70 | ₹2795.90 | ₹2601.00 | ₹2618.60 | -1.55% | |
| ₹2786.00 | ₹2883.40 | ₹2622.60 | ₹2659.70 | -4.53% | |
| ₹3162.90 | ₹3184.30 | ₹2560.00 | ₹2785.00 | -11.95% | |
| ₹3388.70 | ₹3450.00 | ₹3072.50 | ₹3162.60 | -6.67% | |
| ₹3298.00 | ₹3515.70 | ₹3153.90 | ₹3388.10 | +2.73% | |
| ₹2935.30 | ₹3398.00 | ₹2693.90 | ₹3298.60 | +12.38% |
AI Research Briefing
Powered by Gemini · 2026-04-09
GSK's expensive pivot to specialty pharma needs flawless execution to justify its premium valuation.
⚡ WHAT'S HAPPENING NOW (last 2-4 weeks): No major catalysts found after live search. GlaxoSmithKline Pharmaceuticals Ltd submitted its Q4FY26 compliance certificate to stock exchanges. 🧠 CORE STORY (THE REAL GAME): GlaxoSmithKline (GSK) is pivoting towards specialty pharmaceuticals, particularly in oncology and respiratory, while maintaining its base in general medicines. The market is pricing in GSK's ability to successfully transition to higher-margin specialty products and maintain growth amidst global pricing pressures. 🔥 WHAT IS DRIVING THE STOCK: 1. **Specialty Medicines Growth:** GSK's focus on specialty medicines, with sales reaching £13.5B in 2025 (+17%), is a key driver. Oncology sales grew by 43% to £2.0B, and Respiratory, Immunology & Inflammation (RI&I) grew by 18% to £3.8B. 2. **Acquisitions:** GSK has been actively acquiring companies to bolster its pipeline in oncology and RI&I. Recent acquisitions include 35Pharma for $950M and RAPT Therapeutics for $2.2B. 3. **Dividend Increase:** GSK has declared an increased dividend for 2025 of 66p per share and expects 70p per share for 2026, signaling confidence in its financial performance. ⚖️ BULL vs BEAR: Bull: GSK's focus on specialty medicines and strategic acquisitions will drive long-term growth and profitability. The company's strong financial performance and commitment to shareholder returns make it an attractive investment. Bear: GSK faces challenges from supply chain disruptions, regulatory dynamics, and declining growth in general medicines. The high P/E ratio of 44.39x compared to the industry P/E of 31.77x suggests that the stock may be overvalued. Currency fluctuations could also negatively impact earnings. 💣 WHAT MARKET IS PRICING: The market is pricing in continued growth in specialty medicines and successful integration of recent acquisitions. If GSK fails to deliver on these expectations, the stock could face a correction. 🎯 BOTTOM LINE: GSK is betting big on specialty pharma, but rich valuation and execution risks demand caution.
- Focus on specialty medicines driving growth
- Strategic acquisitions bolstering pipeline
- Increased dividend signaling financial confidence
- Successful commercial launches of new specialty drugs
- Positive results from pivotal clinical trials
- Further strategic acquisitions to expand pipeline
- High P/E ratio compared to industry average
- Declining growth in general medicines
- Currency fluctuation risks
FII decreased their holdings by 0.1%, while DII increased their holdings by 0.04%. Promoter holding remains unchanged at 75.0%.
Indian pharmaceutical exports are projected to reach $130 billion by 2030, providing a tailwind for GSK's India operations.
Yes - Free Cash Flow 5Y: ₹5204.49 Cr
GSK's 3-6 month thesis hinges on successful commercial launches and positive clinical trial results. Failure to execute could lead to a significant correction.
Primary Thesis Risk
Failure to successfully transition to specialty pharmaceuticals will decimate the growth story.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
GlaxoSmithKline Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
GlaxoSmithKline Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GLAXO across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (46.87%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (63.25%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (25.52%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Excellent EPS Growth (34.71% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (34.71% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (811.63x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹5204.49 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (75.00%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 44.39x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (3.06% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Peer Comparison - Pharmaceuticals
Compare GlaxoSmithKline Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
58.7/100 | ₹2436.70₹2437 | ₹42320.52₹42320.52 | 44.39Average 44.4 Average | 46.87%Excellent 46.87% Excellent | 63.25%Excellent 63.25% Excellent | 0.02Excellent 0.0 Excellent | 34.71%Excellent 34.71% Excellent | 3.06%Average 3.06% Average | 1.68% | |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1671.00₹1671 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 0.00%Poor 0.00% Poor | 0.07Excellent 0.1 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6286.50₹6287 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 0.00%Poor 0.00% Poor | 0.01Excellent 0.0 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4180.50₹4181 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 0.00%Poor 0.00% Poor | 0.33Excellent 0.3 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1237.20₹1237 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 0.00%Poor 0.00% Poor | 0.01Excellent 0.0 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1237.80₹1238 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 0.00%Poor 0.00% Poor | 0.16Excellent 0.2 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2335.10₹2335 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 0.00%Poor 0.00% Poor | 0.32Excellent 0.3 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹942.20₹942 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 0.00%Poor 0.00% Poor | 0.38Excellent 0.4 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2122.40₹2122 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 0.00%Poor 0.00% Poor | 0.55Good 0.6 Good | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1381.00₹1381 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 0.00%Poor 0.00% Poor | 0.22Excellent 0.2 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5652.00₹5652 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 0.00%Poor 0.00% Poor | 0.18Excellent 0.2 Excellent | 0.00%Average 0.00% Average | 0.00%Average 0.00% Average | 0.00% |
GlaxoSmithKline Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for GlaxoSmithKline Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About GLAXO (GlaxoSmithKline Pharmaceuticals Ltd)
GlaxoSmithKline Pharmaceuticals Ltd is a global healthcare powerhouse dedicated to the discovery, development, and manufacturing of innovative medicines and vaccines. With a legacy... spanning centuries, GSK focuses on addressing some of the world's most significant health challenges, ranging from infectious diseases and respiratory ailments to cancer and immune-related disorders. The company invests heavily in research and development, fostering a culture of scientific excellence and collaboration to accelerate the delivery of life-changing therapies. GSK's commitment extends beyond scientific innovation; it encompasses a deep-rooted dedication to ethical practices, sustainability, and improving global health equity. Through strategic partnerships and global initiatives, GSK strives to ensure that its medicines and vaccines reach those who need them most, regardless of geography or socioeconomic status. GSK's diverse product portfolio encompasses a wide range of therapeutic areas, offering solutions for prevention, treatment, and management of various medical conditions. Its vaccine division plays a crucial role in protecting individuals and communities from preventable diseases, with a strong emphasis on pediatric and adolescent immunization. From groundbreaking oncology drugs targeting specific cancer pathways to novel respiratory therapies designed to alleviate breathing difficulties, GSK's pharmaceuticals are making a tangible difference in the lives of patients worldwide. The company's commitment to innovation extends to its manufacturing processes, leveraging advanced technologies to optimize production efficiency and ensure the highest quality standards. Beyond its core business activities, GSK actively engages in corporate social responsibility initiatives, supporting programs that promote health education, access to healthcare, and community development. The company is dedicated to reducing its environmental impact and operates under stringent ethical guidelines to ensure transparency and accountability in all its operations. GSK recognizes that its success is intrinsically linked to the well-being of the communities it serves and strives to be a responsible corporate citizen, contributing to a healthier and more sustainable future. The firm’s focus is on developing and commercializing cutting-edge pharmaceutical products, which contributes to better patient outcomes.
Company Details
Key Leadership
Corporate Events
Latest News
GLAXO Share Price: Frequently Asked Questions
What is the current share price of GlaxoSmithKline Pharmaceuticals Ltd (GLAXO)?
As of 20 Apr 2026, 08:33 am IST, GlaxoSmithKline Pharmaceuticals Ltd share price is ₹2436.70. The GLAXO stock has a market capitalisation of ₹42.32K (Cr) on NSE/BSE.
Is GLAXO share price Overvalued or Undervalued?
GLAXO share price is currently trading at a P/E ratio of 44.39x, compared to the industry average of 31.77x. Based on this relative valuation, the GlaxoSmithKline Pharmaceuticals Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of GLAXO share price?
The 52-week high of GLAXO share price is ₹3515.70 and the 52-week low is ₹2217.60. These values are updated daily from NSE/BSE price data.
What factors affect the GlaxoSmithKline Pharmaceuticals Ltd share price?
Key factors influencing GLAXO share price include quarterly earnings growth (Sales Growth: -3.05%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is GlaxoSmithKline Pharmaceuticals Ltd a good stock for long-term investment?
GlaxoSmithKline Pharmaceuticals Ltd shows a 5-year Profit Growth of 34.71% and an ROE of 46.87%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.02 before investing in GLAXO shares.
How does GlaxoSmithKline Pharmaceuticals Ltd compare with its industry peers?
GlaxoSmithKline Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare GLAXO share price P/E of 44.39x and ROE of 46.87% against the industry averages to determine competitive standing.
What is the P/E ratio of GLAXO and what does it mean?
GLAXO share price has a P/E ratio of 44.39x compared to the industry average of 31.77x. Investors pay ₹44 for every ₹1 of annual earnings.
How is GLAXO performing according to Bull Run's analysis?
GLAXO has a Bull Run fundamental score of 58.7/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does GLAXO belong to?
GLAXO operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting GlaxoSmithKline Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for GLAXO?
GLAXO has an ROE of 46.87%, which indicates excellent management efficiency. ROE measures how efficiently GlaxoSmithKline Pharmaceuticals Ltd generates profits from shareholders capital.
How is GLAXO debt-to-equity ratio and what does it indicate?
GLAXO has a debt-to-equity ratio of 0.02, which indicates conservative financing with low financial risk.
What is GLAXO dividend yield and is it a good dividend stock?
GLAXO offers a dividend yield of 1.68%, meaning you receive ₹1.68 annual dividend for every ₹100 invested in GlaxoSmithKline Pharmaceuticals Ltd shares.
How has GLAXO share price grown over the past 5 years?
GLAXO has achieved 5-year growth rates of: Sales Growth 3.06%, Profit Growth 34.71%, and EPS Growth 34.71%.
What is the promoter holding in GLAXO and why does it matter?
Promoters hold 75.00% of GLAXO shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in GlaxoSmithKline Pharmaceuticals Ltd.
What is GLAXO market capitalisation category?
GLAXO has a market capitalisation of ₹42321 crores, placing it in the Large-cap category.
How volatile is GLAXO stock?
GLAXO has a beta of N/A. A beta > 1 suggests the GlaxoSmithKline Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is GLAXO operating profit margin trend?
GLAXO has a 5-year average Operating Profit Margin (OPM) of 25.52%, indicating the company's operational efficiency.
How is GLAXO quarterly performance?
Recent quarterly performance shows GlaxoSmithKline Pharmaceuticals Ltd YoY Sales Growth of -3.05% and YoY Profit Growth of 2.57%.
What is the institutional holding pattern in GLAXO?
GLAXO has FII holding of 4.79% and DII holding of 7.75%. Significant institutional holding often suggests professional confidence in the GlaxoSmithKline Pharmaceuticals Ltd stock.